During the past several decades it has become evident that antibiotic products have become increasingly inadequate in their ability treat pathogenic organisms. The reason for this problematic circumstance seems to be that these pathogens have the ability somehow, enigmatically, to change their structures and biological agendas in order to overcome the therapeutic intent of the antibiotic agents. It has been a difficult challenge for pharmaceutical and biotech companies to produce products to solve this enigmatic problem. A new approach may be possible.
Research has shown that most pathogens whether bacterial, viral or fungal, have an interesting commonality. These diverse organisms all gain entrée into the host tissues through the extracellular matrix (ECM). More specifically these pathogens gain entrée to the host tissues through cellular fibronectin. Most of these specie diverse pathogens have “Fibronectin Binding Proteins”. Recent studies have shown that various pathogens enter tissue through a variety of integrins, all of which are lingands for cellular fibronectins. These pathogens also invade a variety of tissues directly through the cellular fibronectin fibrils. The fibronectin binding proteins on these diverse pathogens are therefore the ideal therapeutic targets in order to inhibit pathogenic entrée in the host tissue. There is some empirical and research evidence that non-pathogenic bacteria do not have these specific binding proteins.
The rationale for the ideal therapeutic agent is self-evident. It is Human Cellular Fibronectin. If human cellular fibronectin, used as a therapeutic agent, comes into complete contact with the totality of the offending pathogenic organisms it will lingand with all of their fibronectin binding protein sites thereby satisfying their fibronectin binding proteins functionality’s. Surrounding and adhering to these organisms would inhibit these pathogens from entering the host’s tissues. Non-pathogenic bacteria may not be affected by this agent thereby eliminating untoward side effects such as diarrhea.
Human cellular fibronectin as a therapeutic agent also have several other benefits:
- It is non-toxic.
- It is extremely adhesive.
- It has opsininizing abilities. That is, it surrounds the pathogens and presents them to cells of the immune system for their eventual removal from the circulatory system.
- It has already been used in a FDA clinical trial for periodontal disease and was shown to be safe and effective.
- The human body in all tissues recognizes it as self, because it is self.
- A normal measurable amount of cellular fibronectin is in the human blood stream. The amount of the plasma “cellular fibronectin” increases rapidly during any pathogenic intrusion, which may represent an in place defensive mechanism.
MRSA
C. – diff